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Abstract
Background:  Elevated circulating levels of C-reactive protein (CRP), interleukin (IL)-6 and
fibrinogen (FG) have been repeatedly associated with many adverse outcomes in patients with
chronic obstructive pulmonary disease (COPD). To date, it remains unclear whether and to what
extent systemic inflammation is primary or secondary in the pathogenesis of COPD.
The aim of this study was to examine the association between haplotypes of CRP, IL6 and FGB genes,
systemic inflammation, COPD risk and COPD-related phenotypes (respiratory impairment,
exercise capacity and body composition).
Methods:  Eighteen SNPs in three genes, representing optimal haplotype-tagging sets, were
genotyped in 355 COPD patients and 195 healthy smokers. Plasma levels of CRP, IL-6 and FG were
measured in the total study group. Differences in haplotype distributions were tested using the
global and haplotype-specific statistics.
Results: Raised plasma levels of CRP, IL-6 and fibrinogen were demonstrated in COPD patients.
However, COPD population was very heterogeneous: about 40% of patients had no evidence of
systemic inflammation (CRP < 3 mg/uL or no inflammatory markers in their top quartile). Global
test for haplotype effect indicated association of CRP gene and CRP plasma levels (P = 0.0004) and
IL6 gene and COPD (P = 0.003). Subsequent analysis has shown that IL6 haplotype H2, associated
with an increased COPD risk (p = 0.004, OR = 4.82; 1.64 to 4.18), was also associated with very
low CRP levels (p = 0.0005). None of the genes were associated with COPD-related phenotypes.
Conclusion: Our findings suggest that common genetic variation in CRP and IL6 genes may
contribute to heterogeneity of COPD population associated with systemic inflammation.
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Background
Chronic obstructive pulmonary disease (COPD) is a
multi-component respiratory disease with recognized sys-
temic impact [1]. Numerous studies performed in recent
years provide overwhelming evidence of COPD as a con-
dition characterized by an abnormal inflammatory
response beyond the lungs with evidence of low-grade
systemic inflammation [2-5]. Raised levels of acute phase
proteins like C-reactive protein (CRP), fibrinogen and
pro-inflammatory cytokines such as interleukin (IL)-6
were found in circulation of stable COPD patients [3,6]
and have been shown to be associated with impaired
functional capacity [7], reduced daily physical activity [8]
and decreased health status [5,7,9]. However, given the
cross-sectional nature of most studies performed so far
and possible confounding by a number of lifestyle factors
associated with levels of inflammatory biomarkers [10], it
is not clear whether these proteins are simply markers of
the inflammatory process accompanying chronic diseases
such as COPD or key players in the pathogenesis of dis-
ease.
Genome-wide scans, twin and family studies have shown
that circulating levels of CRP, fibrinogen and IL-6 are her-
itable (estimated as 25%–40%) [11-15]. Furthermore,
recently CRP and FGB polymorphisms/haplotypes have
been described that may partly explain heritability of
acute-phase protein and cytokine levels [16-19]. Genetic
association testing of genotypes, which influence circulat-
ing levels of proteins and directly relate to the outcome of
interest, was suggested as more accurate unconfounded
estimate of whether systemic inflammation levels causally
influence outcome [20].
In the present study we investigate whether common hap-
lotypes in CRP, IL6 and  FGB  (encoding fibrinogen β
chain) genes influence systemic inflammatory status in
COPD, the risk for COPD and, eventually, different dis-
ease-related phenotypes. Some of the results of this study
have been previously reported in the form of an abstract
[21].
Methods
Study participants
The investigation was designed as a case-control associa-
tion study, consisting of unrelated individuals recruited
from the same geographical area (Limburg province, the
Netherlands). A total of 556 Caucasian subjects were
investigated. All subjects were current or former smokers.
Three hundred and sixty-one patients with clinically sta-
ble moderate-to severe COPD entering pulmonary reha-
bilitation (Center for Integrated Rehabilitation of Organ
failure (CIRO), Horn, The Netherlands) were enrolled for
the study. Clinical history of COPD and the degree of the
disease severity were assessed according to the published
Global Initiative for Chronic Obstructive disease (GOLD)
guidelines [22]. One hundred and ninety five healthy (ex-
) smokers were recruited as controls. The healthy control
subjects were volunteers recruited through advertisement
in a local newspaper. Part of the healthy controls were
also recruited through the COSMO study [23]. Inclusion
criteria for both groups were: Caucasian origin, 40 years of
age or older, smoking history of 10 pack-years or more,
completed spirometry and blood sample donation. The
ethical review board of the University Hospital Maastricht
approved the study, and all subjects gave their written
informed consent.
Clinical examination and inflammation measurement
Lung function was determined using spirometry, height
and weight were measured in every participant and body
mass index was calculated. Several COPD-related clinical
characteristics were assessed only in COPD patients based
on standard procedures (see Additional file 1). Plasma
levels of CRP, IL-6 and fibrinogen were measured by high-
sensitivity particle-enhanced immunoassay, ELISA and
coagulation reaction respectively. Further details are pro-
vided in Additional file 1.
TagSNP selection and genotype determination
TagSNPs were selected for genotyping from the SeattleS-
NPs database http://gvs.gs.washington.edu/GVS/ using
resequencing data from 23 unrelated European Ameri-
cans. Polymorphisms with a minor allele frequency of less
5% were not included. Six polymorphisms in CRP, 8 SNPs
in IL6 and 6 SNPs in FGB were selected. For two non-
redundant SNPs of FGB the development of the genotyp-
ing assay failed (rs2227432, rs2227439), leaving 4 tag-
SNPs for the analysis. For further details on DNA
processing and genotyping see Additional file 1.
Statistical analysis
Descriptive statistics and baseline comparisons
Variables are presented as proportions (percentage), mean
± standard deviation (SD) or median (range) depending
on their measurement scale and distribution. Plasma lev-
els of inflammatory mediators were skewed to the right.
They were natural logarithmically transformed to achieve
symmetric distribution. Baseline differences between
groups were analyzed using Student's t test and Mann-
Whitney test for continuous variables and χ2 square test
for categorical variables. Prevalence of systemic inflam-
mation has been accessed by number of inflammatory
markers in the top quartile and by CRP levels. The corre-
lations between inflammatory markers and the different
clinical phenotype were estimated using Pearson's or
Spearman's correlation coefficient. Multiple linear regres-
sion models were performed to search for the best predic-
tors of CRP, IL-6 and fibrinogen levels.BMC Medical Genetics 2009, 10:23 http://www.biomedcentral.com/1471-2350/10/23
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Genetic association analysis
To determine the linkage disequilibrium (LD) we have
calculated the D' statistics between SNPs. Hardy-Weinberg
equilibrium for each tagSNP was tested by the exact χ2 sta-
tistic. SNP rs2069849 in IL6 was excluded from haplotype
analysis because of low allele frequency (3%). To reduce
the problem of multiple testing we selected haplotypes as
major genetic variable. Differences in haplotype distribu-
tions were tested using the global statistic of Schaid under
additive genetic model [24]. If the global haplotype test
achieved a P-value < 0.1, haplotype-specific analysis was
performed. Haplotype-specific effects were estimated
using linear and logistic regression as implemented in the
haplo.stats package in R. Analyses were adjusted for
potentially confounding factors (see Additional file 1 for
full description). P-values less than 0.05 were considered
significant (two-sided).
Eight primary genetic tests were performed. First, each
gene was tested for association with two major outcomes:
either corresponding protein level or COPD. These com-
prised 6 tests. Additionally, given that IL-6 is a major reg-
ulator of hepatic production of CRP and fibrinogen, we
also investigated the association of IL6 haplotypes with
CRP and fibrinogen plasma levels (2 tests). To reduce the
problem of spurious associations due to multiple testing,
Bonferroni correction was applied for those tests (Pcorrected
= 0.05/8 tests = 0.006).
Body-Mass Index, Airflow Obstruction, Dyspnea, and
Exercise Capacity (BODE) index, 6 minute walking dis-
tance (6MWD), maximum workload at the cardiopulmo-
nary test, Medical research council (MRC) score, body
mass index (BMI) and forced expiratory volume in 1 sec
(FEV1) were tested after initial 8 analyses have been per-
formed and treated as secondary outcomes. Secondary
COPD outcomes were not considered for a conservative
Bonferonni correction, because of a high degree of corre-
lation with each other.
Results
Systemic inflammation
Table 1 summarizes the demographic data and baseline
characteristics of study groups. Compared with the
healthy smokers, COPD patients were older, more likely
to be men and had more pack-years smoking. On average,
patients had moderate-to-severe airflow obstruction and
clear functional exercise intolerance.
In general, COPD patients had higher baseline median
levels of circulating inflammatory markers (P < 0.001)
(Table 1). This difference was still significant after adjust-
ment for age, sex, smoking status, BMI and pack-years
smoked. However, the COPD population was very heter-
ogeneous: 27.3% of COPD patients had CRP levels > 10
mg/L, which is a significantly higher proportion than in
healthy smokers (5.2%), whereas about 40% of COPD
patents had no evidence of systemic inflammation as
assessed by CRP levels alone (< 3 mg/L) or by the number
of inflammatory markers in their top quartiles (no mark-
ers in the top quartile).
Table 2 shows the comparison of clinical characteristics
from patients with baseline CRP value < 3 mg/L versus >
3 mg/L. Patients from the "inflammatory" group (CRP > 3
mg/L) were older, more likely to be male, had a higher
BMI, more co morbidities and worse results in the 6
minute walking test. Interestingly, besides age and sex, the
6MWD was negatively associated with all 3 inflammatory
markers in the backward multiple linear regression analy-
ses (see Additional file 2). Correlations between the
inflammatory markers and the functional measures of dis-
ease are shown in Additional file 3.
Haplotype Tagging SNPs and COPD
From the data of SeattleSNPs, we selected 18 SNPs (Table
3) which together tag the 5 most common (frequency >
2.5%) haplotype groups of CRP, the 8 most common hap-
lotype groups of IL6 and the 5 most common haplotype
groups of FGB (Table 4). None of the tagSNPs showed a
significant deviation from Hardy-Weinberg in a control
group, and the allele frequencies were comparable to
those reported in the Seattle SNP panel and other Cauca-
sian populations and individuals of Dutch origin
[18,19,25]. All polymorphisms within each gene showed
a little evidence of historical recombination as measured
by D' (see Additional file 4).
Table 3 shows basic characteristics for SNPs and their
allele frequency distribution in COPD patients and
healthy smokers. Significant difference in allele frequency
between patients and controls was found for the CRP syn-
onymous SNP 2667G/C (rs1800947) and for the IL6
3'UTR SNP 7592G/A (rs1818879). Results of single-SNP
analyses performed for all 18 SNPs for each of the major
outcome are summarized in Table 3 and Additional file 5.
Briefly, an increased risk of COPD was found for carriers
of the minor alleles of the rs1800947 and rs1818879. For
the tri-allelic CRP SNP rs3091244, association with
increased CRP levels was observed. We also identified two
CRP and one IL6 SNPs, which were significantly associ-
ated with decreased CRP levels (see Additional file 5).
Haplotype-based analysis, COPD and systemic 
inflammation phenotypes in COPD patients
Common haplotypes were predicted from genotypic data.
First, global test for haplotype association were performed
for all 3 genes to provide an overall test with 4 outcomes
of interest (Table 4). A significant difference in haplotype
distribution between patients and controls was observedBMC Medical Genetics 2009, 10:23 http://www.biomedcentral.com/1471-2350/10/23
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for IL6 (P = 0.003). There was a trend for association with
COPD for CRP haplotypes (P = 0.09). At the same time,
CRP levels were the most significantly associated with
CRP haplotypes (P = 0.0004) and less strongly with IL6
haplotypes (P = 0.08) (Table 4).
To investigate the cause of these associations further we
calculated haplotype-specific scores and then estimated
haplotype effects relative to the most common haplotype
when all haplotypes were entered into regression model
(Tables 5, 6). In particular, CRP haplotype H3 was associ-
ated with higher risk of being COPD and low CRP levels
when tested against the most common haplotype H4
(Table 5). However, IL6 haplotype H2 was associated with
even higher decrease in CRP levels (Table 6). Moreover,
the IL6 haplotype H2 was differently distributed between
cases and controls (6.2% versus 2.4%, P = 0.0006) and
associated with almost 5 times higher risk of COPD com-
pared to the most common haplotype H4 (OR = 4.82,
95%CI 1.64–4.18, P = 0.004) (Table 6). Thus, the H2 hap-
lotype effect on COPD risk is stronger than the effect of
the IL6 rs1818879 (OR = 1.49, 95%CI 1.08–2.04) (Table
3).
Comparable associations were found when the total
group of cases and controls was considered for analysis of
systemic inflammation levels (N = 550) (data not shown).
Genetic variation and COPD-related phenotypes
Given that inflammatory markers were correlated with
some disease characteristics (see Additional file 3), we fur-
ther studied whether corresponding inflammatory genes
are associated with important quantitative COPD pheno-
types and performed the association analysis for 6 out-
Table 1: Baseline characteristics of COPD patients and healthy controls*
Characteristics Controls
N = 195
COPD
N = 355
P-value
Years of age 54.3 (7.3) 64.2 (9.4) <0.001
Male, N (%) 94 (48) 219 (62) 0.002
Current smoker, N (%) 115 (59%) 90 (25%) <0.001
Tobacco consumption, pack years-smoked 29.6 (14.8) 39.9 (18.5) <0.001
FEV1, liters 3.2 (0.7) 1.1 (0.5) <0.001
FEV1,%pred 103.3 (15.1) 41.9 (16.0) <0.001
FEV1/FVC, % 78.3 (5.3) 42.0 (11.9) <0.001
FVC, liters 4.1 (0.9) 3.0 (0.9) <0.001
FVC,%pred 109.3 (16.8) 86.3 (21.1) <0.001
BMI, kg/m2 26.4 (3.7) 25.0 (5.0) <0.001
Hypertension†, N (%) 33 (17%) 88 (25%) 0.01
PaO2, kPa - 9.2 (1.37)
PaCO2, kPa - 5.5 (0.80)
Long-term oxygen therapy, N (%) - 82 (23.43)
6 minute walking distance, meters - 420.1 (127.9)
Maximum workload, watts - 72.6 (33.9)
Maximum workload,% pred - 56.6 (25.2)
MRC dyspnea score - 3 (2–4)
BODE index 4.3 (2.1)
Systolic blood pressure, mm/Hg - 135.9 (23.31)
Diastolic blood pressure, mm/Hg - 81.1 (13.09)
Charlson co morbidity index‡ - 1 (1–8)
CRP, mg/L 1.3 (0.2–3.19) 4.6 (1.3–11.09) <0.001
IL-6, pg/mL 0.7 (0.45–1.38) 2.1 (1.15–4.24) <0.001
Fibrinogen, g/L 3.3 (3.00–3.60) 3.6 (3.23–3.82) <0.001
Number of plasma markers
in the top quartile:
<0.001
0, N (%) 155 (79.4%) 159 (44.5%)
1, N (%) 29 (14.4%) 88 (24.2%)
2–3, N (%) 10 (5.2%) 118 (31.3%)
CRP < 1 mg/L 93 (47.9%) 68 (19.2%) <0.001
CRP 1–3 mg/L 51 (26.3%) 81 (22.8%)
CRP 3–10 mg/L 40 (20.6%) 109 (30.7%)
CRP > 10 mg/L 10 (5.2%) 97 (27.3%)
*Data presented as mean (standard deviation), median (inter quartile range) or No (%) unless otherwise stated
†Hypertension was defined as blood pressure > 140/90 mmHg or need for antihypertensive treatment.
‡ Median (range)BMC Medical Genetics 2009, 10:23 http://www.biomedcentral.com/1471-2350/10/23
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comes: BODE index, MRC score, BMI, FEV1, maximum
workload and 6MWD. For all 3 genes, no significant asso-
ciation was observed when an overall test of association
was applied, except for a marginal association of the CRP
gene and maximum workload (Table 7). Further testing
showed borderline association of the haplotype 121211
with maximum workload (P = 0.05).
Discussion
Similar to previous studies [4,9], we have shown that cir-
culating levels of CRP, IL-6 and fibrinogen are increased in
clinically stable COPD patients comparing to healthy
(ex)smokers. Importantly, inflammatory markers distri-
bution has shown a striking heterogeneity of COPD pop-
ulation in relation to the systemic inflammatory response.
Furthermore, we observed a significant association
between IL6 and CRP haplotypes and CRP levels in COPD
patients as well as in the total study group, similar to the
previous population-based and clinical studies
[16,26,27]. Surprisingly, in our study those haplotypes
were not related to any of COPD functional phenotype
including BMI and 6MWD, which were the most strongly
correlated with CRP plasma levels similar to the previous
reports [4,5,9]. However, when compared to the controls,
a new association of IL6 gene and COPD was identified.
In particular, IL6 haplotype H2 (6.2% of cases) was asso-
ciated with 5 times higher risk of COPD and significant
decrease in CRP levels in COPD patients. To our knowl-
edge, the present study is the first haplotype-based associ-
ation analysis examining common genetic variation in
CRP, IL6 and FGB genes on COPD risk and circulating lev-
els of inflammatory markers in COPD patients and
healthy smokers.
Although presence of systemic inflammation has been
widely accepted in the last years as an essential character-
istic of COPD [3,28], our data clearly show that levels of
CRP and 2 other widely studied in COPD markers, IL-6
and fibrinogen, vary significantly across the COPD popu-
lation. This gives us strong evidence that not all COPD
patients have a manifested low-grade systemic inflamma-
tory response. In fact, comparable findings was reported
in our previous study of CRP in relation to COPD pheno-
types [7]. Further evidence of heterogeneity in relation to
Table 2: Comparison of clinical parameters between patients with initial CRP levels ≤3 mg/L versus > 3 mg/L
Characteristics CRP   3 mg/L
N = 146
CRP > 3 mg/L
N = 209
P-value
Years of age 62.1 (8.2) 65.7 (9.8) < 0.001
Male, N (%) 77 (53%) 142 (68%) 0.004
Current smoker, N (%) 40 (27%) 50 (24%) 0.460
Tobacco consumption, pack years-smoked 40.3 (19.0) 39.6 (18.2) 0.703
FEV1, liters 1.1 (0.5) 1.1 (0.5) 0.922
FEV1,%pred 41.6 (15.9) 41.9 (15.9) 0.846
FEV1/FVC, % 41.0 (11.8) 42.7 (11.8) 0.172
FVC, liters 3.0 (1.0) 3.0 (0.9) 0.884
FVC,%pred 87.5 (22.5) 85.4 (20.3) 0.373
BMI, kg/m2 24.0 (4.4) 25.7 (5.4) 0.001
PaO2, kPa 9.3 (1.5) 9.1 (1.3) 0.259
PaCO2, kPa 5.4 (0.8) 5.5 (0.8) 0.342
Long-term oxygen therapy, N (%) 30 (21%) 52 (25%) 0.205
6 minute walking distance, meters 445.9 (121.2) 401.1 (129.3) 0.001
Maximum workload, watts 77.2 (34.7) 69.2 (33.0) 0.037
Maximum workload,% pred 57.4 (23.6) 56.0 (26.4) 0.636
MRC dyspnea score 2 (2–4) 3 (2–4) 0.108
BODE index 4.1 (2.1) 4.4 (2.1) 0.264
Systolic blood pressure, mm/Hg 134.7 (21.7) 136.8 (24.4) 0.412
Diastolic blood pressure, mm/Hg 80.7 (12.5) 81.4 (13.5) 0.647
Charlson co morbidity index † 1 (1–7) 1 (1–8) 0.007
GOLD stages (%):
Mild 2.1% 2.4% 0.891
Moderate 27.4% 23.9%
Severe 35.6% 38.3%
Very severe 34.9% 35.4%
CRP, mg/L 1.1 (0.6–1.9) 9.4 (5.8–16.0) < 0.001
IL-6, pg/mL 1.3 (0.7–2.1) 3.5 (1.6–5.1) < 0.001
Fibrinogen, g/L 3.3 (3.0–3.6) 3.7 (3.4–4.0) < 0.001
*Data presented as mean (standard deviation), median (inter quartile range) or No (%) unless stated otherwise
† Median (range)BMC Medical Genetics 2009, 10:23 http://www.biomedcentral.com/1471-2350/10/23
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CRP comes from a recent intervention study [29], which
has shown that COPD patients segregate for provastatin-
responders (CRP > 1 mg/uL) and non-responders (CRP <
1 mg/L) based on their baseline CRP levels. Those non-
responders may represent the distinct COPD subpopula-
tion with low CRP levels which has impaired immune
response to bacteria, viruses and other agents. Interest-
ingly, our findings also suggest that low CRP levels may be
associated with significantly higher COPD risk in carriers
of a specific IL6 haplotype. Given that lung-expressed CRP
could be up regulated by cytokines and has shown cyto-
protective effect in innate immune response against bacte-
ria and particulate matter [30-32], CRP and IL6 haplo-
types should be further studied in relation to the local
impairment in COPD.
In previous reports there seems to be inconsistency about
the relationship involving biomarkers levels, correspond-
ing genes and COPD phenotypes. On the one hand, sig-
nificant associations between the plasma levels of CRP, IL-
6 and fibrinogen and COPD phenotypes have been
observed [2,7,8,33]. Yet, on the other, no relationship
Table 3: Tagging SNPs characteristics and single SNP association analysis for COPD
dbSNP No. tagSNP* Gene region Minor allele frequency P-value alleles† OR adj‡ genotypes
(95%CI)
P-value genotypes
Controls COPD
IL6 gene (7p21-p15)
rs2069825 205CT/- 5'flanking 0.42 0.37 0.11 0.87
(0.64–1.17)
0.35
rs2069827 321G/T 5'flanking 0.10 0.07 0.10 0.67
(0.39–1.14)
0.14
rs1800797 1086G/A 5'flanking 0.44 0.39 0.12 0.86
(0.64–1.16)
0.32
rs2069840 3437C/G intron 0.34 0.36 0.52 1.04
(0.76–1.42)
0.81
rs1554606 3572G/T intron 0.46 0.42 0.19 0.84
(0.62–1.13)
0.25
rs2069849 6021C/T synonymous 0.03 0.02 0.33 0.51
(0.19–1.36)
0.18
rs2069861 6519C/T 3'flanking 0.11 0.09 0.24 0.93
(0.57–1.52)
0.77
rs1818879 7592G/A 3'flanking 0.32 0.39 0.02 1.49
(1.08–2.04)
0.01
CRP gene (1q21-q23)
rs3091244 1440C/T 5'flanking 0.30 0.31 0.08 1.01
(0.73–1.40)
0.94
1440C/A 0.06 0.08 1.57
(0.88–2.79)
0.12
rs1800947 2667G/C synonymous 0.05 0.08 0.03 1.80
(0.96–3.37)
0.06
rs1130864 3014C/T 3' UTR 0.30 0.31 0.65 1.05
(0.76–1.46)
0.76
rs1205 3872G/A 3'-flanking 0.35 0.33 0.41 0.98
(0.73–1.32)
0.91
rs2808630 5237A/G 3'-flanking 0.29 0.27 0.55 0.83
(0.60–1.15)
0.27
rs3090077 6469A/C 3'-flanking 0.05 0.08 0.15 1.59
(0.86–2.96)
0.14
FGB gene (4q28)
rs1800791 1038G/A 5' flanking 0.18 0.17 0.63 0.80
(0.55–1.18)
0.26
rs1800788 1643C/T 5' flanking 0.18 0.21 0.31 1.36
(0.94–1.95)
0.10
rs1800787 1744C/T 5' flanking 0.21 0.20 0.59 1.10
(0.75–1.61)
0.62
rs2227421 9952A/C 3' UTR 0.31 0.33 0.59 1.03
(0.74–1.42)
0.87
* TagSNPs are numbered by position in sequences AF449713 for CRP, AF372214 for IL6 and AF388026 for FGB. Base change common allele/rare 
allele.
† P value is for the test of allele counting in cases versus controls.
‡ Logistic regression analysis was adjusted for age, sex and tobacco consumption (pack-years smoked)BMC Medical Genetics 2009, 10:23 http://www.biomedcentral.com/1471-2350/10/23
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between the polymorphisms influencing the protein lev-
els and COPD phenotypes could be demonstrated in the
current and some other smaller studies [34,35]. Interest-
ingly, three recent mRNA/protein profiling studies in
quadriceps and vastus lateralis of COPD patients [36-38]
failed to confirm a common hypothesis that increased
expression of pro-inflammatory cytokines (IL-6, IL-8, IL-1
and TNF-α) induce muscle atrophy in COPD patients
with muscle weakness. Several phenomena might explain
differences between studies of inflammatory genes,
mRNA and proteins in COPD. It is well-known that
results of observational studies of inflammatory markers
might be confounded because of residual association with
numerous non-diseases related factors (i.e. lifestyle and
socioeconomic) [10,39]. Thus, association of CRP or IL6
variation with disease phenotype may suggest a causal
relationship between CRP levels and disease [20]. How-
ever, genetic variation in CRP actually only explains a rel-
Table 4: Frequency distribution in patients and controls and global association tests for haplotypes of IL6, CRP and FGB
Gene Haplotype* Controls
%
COPD
%
Global test P-values†
COPD Ln
(IL-6)
Ln
(CRP)
Ln
(fibrinogen)
IL6 H1 1111111 17.8 16.1 0.003 0.80 0.08 0.73
H2 1111112 2.4 6.2
H3 1112111 4.8 10.2
H4 1112112 27.8 25.0
H5 2121211 20.1 16.1
H6 2121221 10.4 7.7
H7 2221211 10.1 6.3
CRP H1 111121 28.7 26.6 0.09 Not tested 0.0004 Not tested
H2 111211 30.3 24.2
H3 121211 4.9 8.2
H4 212111 29.7 30.4
H5 311112 5.4 7.3
FGB H1 1111 11.9 10.3 0.28 Not tested Not tested 0.72
H2 1112 31.2 32.8
H3 1121 21.0 19.2
H4 1211 18.2 20.9
H5 2111 17.4 16.2
* 1 codes the common allele and 2 codes the minor allele. IL6 loci are presented in the order rs2069825, rs2069827, rs1800797, rs2069840, 
rs1554606, rs2069861 and rs1818879. CRP loci are presented in the order rs3091244, rs1800947, rs1130864, rs1205, rs2808630 and rs3090077. 
FGB loci are presented in the order rs1800791, rs1800788, rs1800787 and rs2227421
† Global test p-value from haplo.score for overall association between haplotypes and trait. The COPD analysis was adjusted for age, sex and 
tobacco consumption (pack-years smoked). Inflammatory markers levels analyses were adjusted for marker-specific clinical covariates: age, sex and 
6MWD (all genes) and BMI (only for CRP).
Table 5: Association of CRP haplotypes with COPD and ln(CRP)
COPD* Ln(CRP) †
Haplotype OR (95%CI) P-value Coefficient ± SE P-value
H1 0.85 (0.57–1.27) 0.42 -0.33 ± 0.13 0.01
H2 0.86 (0.64–1.16) 0.43 -0.13 ± 0.13 0.34
H3 1.64 (0.83–3.27) 0.16 -0.58 ± 0.20 0.004
H4 REFERENT REFERENT
H5 1.35 (0.69–2.65) 0.38 -0.02 ± 0.21 0.92
Others‡ 2.91 (0.77–0.98) 0.12 0.66 ± 0.27 0.01
* Logistic regression analyses were adjusted for age, sex and tobacco 
consumption (pack-years smoked).
† Linear regression analyses were adjusted for age, sex, BMI and 
6MWD.
‡ Rare haplotypes (frequency < 2.5%) were coded in aggregate as 
"others"
Table 6: Association of IL6 haplotypes with COPD and ln(CRP)
COPD * Ln (CRP) †
Haplotype OR (95%CI) P-value Coefficient ± SE P-value
H1 0.92 (0.56–1.51) 0.75 0.005 ± 0.17 0.98
H2 4.82 (1.64–4.18) 0.004 -0.94 ± 0.27 0.0005
H3 1.71 (0.85–3.44) 0.13 -0.12 ± 0.21 0.54
H4 REFERENT REFERENT
H5 1.01 (0.64–1.60) 0.95 0.01 ± 0.17 0.93
H6 0.93 (0.51–1.67) 0.80 -0.36 ± 0.22 0.10
H7 0.71 (0.37–1.36) 0.3 -0.02 ± 0.24 0.94
Others‡ 1.48 (0.79–2.78) 0.22 -0.07 ± 0.20 0.73
* Logistic regression analyses were adjusted for age, sex and tobacco 
consumption (pack-years smoked).
† Linear regression analyses were adjusted for age, sex, BMI and 
6MWD.
‡ Rare haplotypes (frequency < 2.5%) were coded in aggregate as 
"others"BMC Medical Genetics 2009, 10:23 http://www.biomedcentral.com/1471-2350/10/23
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atively small proportion of CRP levels variation (< 3%),
compared with other environmental or genetic factors
[16,26,40]. Moreover, given the fact that COPD might
share systemic inflammatory phenotype with cardiovas-
cular disease, cancer and diabetes [41,42], which are
known co morbidities of COPD, conflicting association
data may be caused by different composition of the COPD
populations used across different studies. Lastly, acute-
phase and pro-inflammatory cytokine genes may be only
modifiers of other, not widely studied, inflammatory
genes, which are critically involved in COPD pathogene-
sis. Further hypothesis-free genome-wide high-through-
put screening and gene expression profiling studies are
needed to validate existing and find new candidate mark-
ers characterizing distinct clinical profiles of multi-faced
COPD population.
Our study has several strengths. It is the first one that has
been specifically designed to evaluate relationship
between systemic inflammation and COPD on both
genetic and protein level. For this purpose, both standard
outcomes (COPD diagnosis and lung function) as well as
functional disease-related phenotypes (exercise capacity
and body composition) were taken into account. We used
a tagging SNP based approach capturing all common var-
iability across the genes of interest to investigate whether
genetic variation in the genes of interest influences the risk
of COPD. Next this study is based on a well-characterized
ethnically homogeneous cohort of stable COPD patients
and spirometry-proved healthy smokers collected from
the same geographic region.
In our analysis of 3 genes in relation to 4 primary out-
comes it is possible but unlikely that results were false
positives obtained due to a type I error inflation. It is
worth mentioning, two associations (IL6 haplotypes and
COPD, global P = 0.003, CRP haplotypes and ln(CRP),
global P = 0.0004) were still significant after applying the
conservative Bonferroni correction. In addition, these
associations remained also significant at P < 0.002 after
permutation tests with at least 10000 simulations. Never-
theless, all reported associations between COPD and CRP
and IL6 genes require replication in other independent
studies. Similar to our results, three previous studies of the
IL6 gene could not find any association between COPD
and the SNPs rs1800795 and rs1800797 [43-45]. Interest-
ingly, a new association was found with the IL6 SNP
rs1800796 in COPD patients from Spain [44]. Because of
a low allele frequency in Europeans (4%), this SNP was
not selected for current study; however, further studies
using large samples size of Dutch COPD patients are
required to replicate this new association.
There are also some limitations of the present study. First,
the patients with COPD included in the study were
assessed to enter pulmonary rehabilitation and had pre-
dominantly moderate-to-severe stages of COPD. This
could affect generalizability of our results. Next, a rela-
tively small sample size could have underpowered some
observed genetic associations. Namely, IL6  association
with CRP levels and CRP association with COPD were
marginally significant in the overall testing but have
shown strong haplotype-specific effects in further analy-
sis. Furthermore, as a result of the failure of 2 FGB tag
SNPs for genotyping we were not able to discriminate one
common (defined by rs2227439) and one rare (carrying
the minor allele of rs2227432) haplotypes of the FGB
gene [19]. They were non-discriminative from the FGB
haplotypes 1111 and 1121, respectively.
It is also noticeable, that, although we found an increased
risk of COPD for the IL6 H2 carriers, the functional SNP
causing this risk still has to be identified. IL6 haplotype
H2 is tagged by the minor allele of rs1818879. However,
it is unlikely, that this SNP located in 3'UTR region of IL6,
is functional because no association between haplotype
Table 7: COPD-related phenotypes and global association tests (P-values) for haplotypes of IL6, CRP and FGB
Phenotype*
Gene BODE index MRC score 6MWD, meters Maximum workload, Watts BMI, Kg/m2 FEV1, L
IL6 0.38 0.41 0.48 0.81 0.66 0.22
CRP 0.33 0.41 0.11 0.06 0.56 0.70
FGB 0.74 0.61 0.61 0.64 0.44 0.72
*Global association tests were adjusted for marker-specific clinical covariates selected by backward linear regression. Age and sex were included in 
all final models.
Other covariates included in regression models per phenotype:
BODE index: smoking status (former/current), PCO2 (kPa)
MRC score: FEV1 (liters), smoking status (former/current)
6MWD: FEV1 (liters), Charlson co morbidity index, diastolic blood pressure, smoking status (former/current).
Maximum workload: FEV1 (liters), Charlson co morbidity index, diastolic blood pressure, PCO2 (kPa), height.
BMI: FEV1 (liters), smoking status (former/current), diastolic blood pressure, PCO2 (kPa)
FEV1: Height, systolic and diastolic blood pressure, PCO2 (kPa) and PO2 (kPa).BMC Medical Genetics 2009, 10:23 http://www.biomedcentral.com/1471-2350/10/23
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H4 (tagged by the combination of rs2069840 and
rs1818879) and COPD risk was found. Most likely, the
functional SNP lies on the IL6 H2 haplotype and was not
genotyped in our study. Future resequencing of IL6 haplo-
type H2 carriers may help to identify functional SNP(s).
Given that a recent genome-wide association study [46]
has found a SNP in IL-6 receptor gene as one of the top
associated with six lung function phenotypes and the
association we found between COPD and IL6  gene, it
would be worthwhile to study IL-6 pathway further [47].
Conclusion
In conclusion, CRP and IL6 haplotypes were shown to be
associated with systemic inflammation and COPD but
not with exercise capacity, dysnoea, BMI and BODE index.
Future studies are needed to replicate the observed associ-
ations in large well-defined COPD cohorts.
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